An Open-label Safety, Tolerability, and Pharmacokinetics Study of Eteplirsen in Young Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Eteplirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Sarepta Therapeutics
- 19 Jul 2017 Status changed from not yet recruiting to recruiting.
- 12 Jul 2017 Status changed from planning to not yet recruiting.
- 03 Oct 2016 New trial record